// App-Quantinova.ai

2504 : Assessing the efficacy of the anti metabolic drug, CPI-613, for targeting of ovarian cancer stem cells

Researchers

Presenter

  • Chiara Bellio

Principal Investigators

  • Rosemary Foster

  • Whitfield B. Growdon

  • Bo R. Rueda

Medical Centers

  • Massachusetts General Hospital, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • High-grade serous carcinoma

  • Gynaecological cancer

  • Solid malignancies

Biomarkers

  • Prominin 1

  • KIT Proto-Oncogene, Receptor Tyrosine Kinase

Drug/Treatment

  • Olaparib

  • CPI-613

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved